Latest revenue
$8.0M
as of 2026-03-31
Latest net income
$-14.3M
as of 2026-03-31
Net margin
-178.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- —
- Enterprise value
- —
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $4.94
- 52-wk low
- $1.90
- Beta
- —
- Shares out
- —
5-year trend
What this company does
Item 1. Business. Defining the future of pharmaceutical quality control We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing. Overview We are an innovative life sciences technology company providing mission critical…
AI summary unavailable — showing raw filing excerpt
Generated from RPID's filing dated 2026-03-12
Key risks
Table of Contents Item 1A. Risk Factors. Our business involves significant risks. Stockholders should carefully consider the risks and uncertainties described below and the other information in this Annual Report on Form 10-K. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our Class A common stock could decline and stockholders could lose all or part of their investment. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. See “Forward-Looking Statements.” Our actual results could differ materially and…
AI summary unavailable — showing raw filing excerpt
Generated from RPID's filing dated 2026-03-12
Profitability
Operating margin
-141.1%
20.7%Net margin
-140.3%
16.1%Return on equity
-141.9%
128.1%Return on assets
-63.0%
31.8%Leverage
Debt / equity
1.25×
314.2%Long-term debt / equity
0.57×
Debt / assets
55.6%
139.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $8.0M | +11.1% | $-14.3M | -26.8% | -178.3% |
Q4 2025 2025-12-31 | $11.3M | +37.3% | $-12.5M | -29.1% | -111.0% |
Q3 2025 2025-09-30 | $7.8M | +3.1% | $-11.5M | -1.7% | -146.7% |
Q2 2025 2025-06-30 | $7.3M | +9.7% | $-11.8M | +5.7% | -163.1% |
Q1 2025 2025-03-31 | $7.2M | +28.4% | $-11.3M | +15.5% | -156.2% |
Q4 2024 2024-12-31 | $8.2M | — | $-9.7M | — | -118.0% |
Q3 2024 2024-09-30 | $7.6M | +23.7% | $-11.3M | +15.5% | -148.7% |
Q2 2024 2024-06-30 | $6.6M | +32.3% | $-12.6M | +10.3% | -189.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on RPID — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.3M
Net activity
−$1.3M
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns RPID
Institutional value
$7.2M
Total shares held
3.2M
Distinct holders
16
-25 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 982.5K | $2.2M | — | New |
| 2 | ESSEX INVESTMENT MANAGEMENT CO LLC | 883.9K | $2.0M | +821.6K (+1318.2%) | Added |
| 3 | Evernest Financial Advisors, LLC | 432.5K | $1.0M | +307.5K (+246.0%) | Added |
| 4 | SEI INVESTMENTS CO | 284.8K | $646.5K | +191.2K (+204.2%) | Added |
| 5 | BlackRock, Inc. | 157.2K | $356.9K | +566 (+0.4%) | Added |
| 6 | JANE STREET GROUP, LLC | 132.9K | $301.7K | +27.6K (+26.2%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 109.7K | $249.0K | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 87.6K | $198.7K | +31.4K (+55.9%) | Added |
| 9 | Temasek Holdings (Private) Ltd | 21.8K | $49.5K | — | New |
| 10 | Catalyst Funds Management Pty Ltd | 21.2K | $48.1K | — | New |
| 11 | Hudson Bay Capital Management LP | 12.5K | $28.4K | — | New |
| 12 | Vanguard Global Advisers, LLC | 11.6K | $26.4K | — | New |
| 13 | UBS Group AG | 11.3K | $25.5K | +11.2K (+27343.9%) | Added |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 9.3K | $21.2K | -1.8K (-16.0%) | Trimmed |
| 15 | JPMORGAN CHASE & CO | 109 | $242 | +0 (+0.0%) | No change |
| 16 | SBI Securities Co., Ltd. | 15 | $34 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once RPID's latest filing finishes processing.